Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.
0/5 보강
APA
Munz N, Arribas AJ, et al. (2025). Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.. British journal of haematology, 207(6), 2550-2552. https://doi.org/10.1111/bjh.70185
MLA
Munz N, et al.. "Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.." British journal of haematology, vol. 207, no. 6, 2025, pp. 2550-2552.
PMID
41057281 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
- A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.
- Breast Implant-Associated Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.
- Prognostic Value of the CALLY Index in Diffuse Large B-Cell Lymphoma: Linking Inflammation, Nutrition, and Tumor Biology.
- Prognostic impact of smoking and alcohol consumption in male patients with diffuse large B-cell lymphoma: a multicenter retrospective study.
- The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-X in DLBCL.